<DOC>
	<DOCNO>NCT02367014</DOCNO>
	<brief_summary>This study Phase 1/2 , multi-center , randomize , double-blind , multiple ascend dose , placebo-controlled study , enrol anticipate 36 subject mitochondrial myopathy associate genetically confirm mitochondrial disease evaluate safety , tolerability , pharmacokinetics ( PK ) , preliminary efficacy MTP-131 patient population .</brief_summary>
	<brief_title>A Study Investigating Safety , Tolerability , Efficacy MTP-131 Treatment Mitochondrial Myopathy</brief_title>
	<detailed_description />
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Mitochondrial Diseases</mesh_term>
	<mesh_term>Mitochondrial Myopathies</mesh_term>
	<criteria>Diagnosis mitochondrial disease believe impair mitochondrial respiratory chain . Eligibility require prior genetic confirmation mitochondrial disease . Diagnosis mitochondrial myopathy judge Investigators due exist mitochondrial disease . Subject must able complete Screening Visit 6MWT . Women childbearing potential must agree use birth control specify protocol date sign ICF two month last dose study drug . Eligible subject may require stay overnight clinical research center duration study participation last 7 consecutive day . Any prior current medical condition , judgment Investigator , would prevent subject safely participate and/or complete study requirement . Hospitalized ( admit inpatient ) within 1 month prior Baseline Visit . A history type 1 diabetes mellitus ( T1DM ) . Uncontrolled Type 1 ( T1DM ) Type 2 diabetes mellitus ( T2DM ) , opinion investigator . A creatinine clearance &lt; 45 mL/min calculate Cockcroft Gault equation . Requires pacemaker , defibrillator , undergone cardiac surgery within 2 year Screening Visit . Uncontrolled hypertension ( &gt; 160 mmHg systolic &gt; 100 mmHg diastolic ) Screening Visit . Subject participate another interventional clinical trial within 3 month screen visit currently enrol noninterventional clinical trial judge Investigator incompatible current trial . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Mitochondrial Myopathy</keyword>
	<keyword>Primary Mitochondrial Disease</keyword>
	<keyword>Bendaviaâ„¢</keyword>
	<keyword>elamipretide</keyword>
</DOC>